<- Go Home
Instil Bio, Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Market Cap
$150.2M
Volume
77.0K
Cash and Equivalents
$6.7M
EBITDA
-$56.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$92.00
52 Week Low
$9.62
Dividend
N/A
Price / Book Value
0.85
Price / Earnings
-1.99
Price / Tangible Book Value
0.85
Enterprise Value
$114.4M
Enterprise Value / EBITDA
-2.11
Operating Income
-$60.8M
Return on Equity
36.63%
Return on Assets
-12.40
Cash and Short Term Investments
$121.1M
Debt
$85.3M
Equity
$176.3M
Revenue
N/A
Unlevered FCF
-$19.3M
Sector
Biotechnology
Category
N/A